13 September 2018

AstraZeneca and MedImmune, its global biologics research and development arm, today announced that new data from the BORA Phase III extension trial of Fasenra (benralizumab) is among 43 company abstracts accepted for oral and poster presentation at the European Respiratory Society (ERS) International Congress 2018, 15-19 September in Paris. A late-breaking oral presentation of the BORA Phase III trial evaluates the long-term safety and efficacy of Fasenra as an add-on treatment for patients with severe eosinophilic asthma who had previously completed one of the pivotal SIROCCO or CALIMA Phase III trials.

Read more